Back to results
US 11,957,677 B2Granted
Cancer treatment using FGFR inhibitors and PLK1 inhibitors
AssigneeCardiff Oncology, Inc.
InventorsMaya Ridinger, Mark Erlander, Anju Karki
Life of this patent
Estimating the term…
Abstract
Provided include methods, compositions and kits for treating cancer in a subject. The method can comprise administrating an FGFR inhibitor (for example, AZD4547) and a PLK1 inhibitor (for example, onvansertib) to the subject in a manner sufficient to inhibit progression of the cancer.
Claims18
A method of therapeutically treating lung cancer or gastric cancer, the method comprising:
- administrating a fibroblast growth factor receptor (FGFR) inhibitor and onvansertib to a subject with the lung cancer or the gastric cancer, thereby inhibiting progression of the lung cancer or the gastric cancer.
A method of sensitizing lung cancer or gastric cancer cells to an FGFR inhibitor, the method comprising:
- contacting the lung cancer or gastric cancer cells with a composition comprising onvansertib, thereby sensitizing the lung cancer or gastric cancer cells to the FGFR inhibitor.
Dependencies are inferred from the claim text.